NCT05794503View on ClinicalTrials.gov

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

PHASE4CompletedINTERVENTIONAL

Enrollment

235

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Urinary Retention PostoperativeLaparoscopic CholecystectomyNeuromuscular BlockadeSugammadexNeostigmineNeuromuscular Blocking AgentsPhysiological Effects of Drugs

Interventions

DRUG

Neostigmine

Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.

DRUG

Sugammadex

Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex

Trial Locations (1)

75390-9068

UT Southwestern Medical Center, Dallas

All Listed Sponsors

lead

University of Texas Southwestern Medical Center

OTHER

NCT05794503 - Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex | Biotech Hunter | Biotech Hunter